Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KROS NASDAQ:MLYS NYSE:OGN NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKROSKeros Therapeutics$14.49-4.0%$15.27$9.12▼$72.37$612.89M0.97426,248 shs5.81 million shsMLYSMineralys Therapeutics$43.35+1.3%$29.55$8.24▼$44.38$2.84B0.41.45 million shs1.50 million shsOGNOrganon & Co.$9.55-0.1%$9.93$8.01▼$19.05$2.49B0.633.72 million shs2.89 million shsRXRXRecursion Pharmaceuticals$6.79+15.3%$5.10$3.79▼$12.36$2.56B0.9148.14 million shs179.49 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKROSKeros Therapeutics-3.98%-9.21%-6.82%+0.91%-76.01%MLYSMineralys Therapeutics+1.29%+15.63%+19.72%+202.30%+216.42%OGNOrganon & Co.-0.26%-6.85%-8.06%-0.99%-47.07%RXRXRecursion Pharmaceuticals+15.28%+11.49%+42.35%+23.01%+1.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKROSKeros Therapeutics$14.49-4.0%$15.27$9.12▼$72.37$612.89M0.97426,248 shs5.81 million shsMLYSMineralys Therapeutics$43.35+1.3%$29.55$8.24▼$44.38$2.84B0.41.45 million shs1.50 million shsOGNOrganon & Co.$9.55-0.1%$9.93$8.01▼$19.05$2.49B0.633.72 million shs2.89 million shsRXRXRecursion Pharmaceuticals$6.79+15.3%$5.10$3.79▼$12.36$2.56B0.9148.14 million shs179.49 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKROSKeros Therapeutics-3.98%-9.21%-6.82%+0.91%-76.01%MLYSMineralys Therapeutics+1.29%+15.63%+19.72%+202.30%+216.42%OGNOrganon & Co.-0.26%-6.85%-8.06%-0.99%-47.07%RXRXRecursion Pharmaceuticals+15.28%+11.49%+42.35%+23.01%+1.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKROSKeros Therapeutics 2.40Hold$30.00107.04% UpsideMLYSMineralys Therapeutics 2.57Moderate Buy$43.500.35% UpsideOGNOrganon & Co. 2.50Moderate Buy$17.3381.54% UpsideRXRXRecursion Pharmaceuticals 2.17Hold$7.256.77% UpsideCurrent Analyst Ratings BreakdownLatest KROS, MLYS, OGN, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025KROSKeros TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025MLYSMineralys TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OGNOrganon & Co.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025RXRXRecursion PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025KROSKeros TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025MLYSMineralys TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025OGNOrganon & Co.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025RXRXRecursion PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/11/2025MLYSMineralys TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $50.009/11/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/9/2025MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $52.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKROSKeros Therapeutics$3.55M165.80N/AN/A$14.11 per share1.03MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/AOGNOrganon & Co.$6.40B0.39$4.92 per share1.94$1.83 per share5.22RXRXRecursion Pharmaceuticals$58.84M50.10N/AN/A$2.61 per share2.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKROSKeros Therapeutics-$187.35M$0.3146.74N/A1.948.06%2.96%2.74%11/5/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.56N/AN/AN/AN/A-70.44%-65.51%11/10/2025 (Estimated)OGNOrganon & Co.$864M$2.693.552.550.8611.15%163.88%6.99%10/30/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)Latest KROS, MLYS, OGN, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/10/2025Q3 2025MLYSMineralys Therapeutics-$0.71N/AN/AN/AN/AN/A11/5/2025Q3 2025KROSKeros Therapeutics-$1.11N/AN/AN/A$4.22 millionN/A11/5/2025Q3 2025RXRXRecursion Pharmaceuticals-$0.35N/AN/AN/A$19.36 millionN/A10/30/2025Q3 2025OGNOrganon & Co.$0.93N/AN/AN/A$1.57 billionN/A8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78-$0.66+$0.12-$0.66N/AN/A8/6/2025Q2 2025KROSKeros Therapeutics-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 million8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKROSKeros TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.84%N/A2.97%N/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ALatest KROS, MLYS, OGN, and RXRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKROSKeros TherapeuticsN/A21.1121.11MLYSMineralys TherapeuticsN/A15.1215.12OGNOrganon & Co.11.981.651.13RXRXRecursion Pharmaceuticals0.023.583.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKROSKeros Therapeutics71.56%MLYSMineralys Therapeutics84.46%OGNOrganon & Co.77.43%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipKROSKeros Therapeutics20.60%MLYSMineralys Therapeutics25.56%OGNOrganon & Co.1.96%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKROSKeros Therapeutics10040.62 million32.25 millionOptionableMLYSMineralys Therapeutics2866.30 million49.35 millionOptionableOGNOrganon & Co.4,000259.97 million254.87 millionNot OptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableKROS, MLYS, OGN, and RXRX HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 12.3% - Time to Buy?October 15 at 1:16 PM | marketbeat.comBiotech Stocks To Consider - October 15thOctober 15 at 1:03 PM | marketbeat.comRecursion Pharmaceuticals call volume above normal and directionally bullishOctober 14 at 6:38 PM | msn.comPromising Biotech Stocks To Follow Today - October 14thOctober 14 at 1:02 PM | marketbeat.com2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk (RXRX)...October 13 at 12:12 PM | marketbeat.com4 Healthcare Stocks to Buy NowOctober 12, 2025 | fool.comRecursion Pharmaceuticals (RXRX): Assessing Valuation with AI Strategy in Focus Ahead of Key CEO PresentationOctober 12, 2025 | finance.yahoo.comTraders Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)October 10, 2025 | americanbankingnews.comRecursion Pharmaceuticals: Recent Gains Are Mysterious Given A Lack Of Overall ProgressOctober 9, 2025 | seekingalpha.comRecursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI ConferenceOctober 9, 2025 | insidermonkey.comWeiss Ratings Reiterates "Sell (D-)" Rating for Recursion Pharmaceuticals (NASDAQ:RXRX)October 9, 2025 | marketbeat.comInvestors Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)October 8, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.8% - Here's What HappenedOctober 8, 2025 | marketbeat.comBiotech Stocks To Follow Today - October 8thOctober 8, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory October 8, 2025 | insidermonkey.comRecursion Pharmaceuticals, Inc. (RXRX): A Bull Case TheoryOctober 8, 2025 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should KnowOctober 7, 2025 | msn.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from AnalystsOctober 3, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?October 3, 2025 | zacks.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 9.5% - What's Next?October 2, 2025 | marketbeat.comNeedham Reiterates a Buy on Recursion Pharmaceuticals (RXRX)September 30, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKROS, MLYS, OGN, and RXRX Company DescriptionsKeros Therapeutics NASDAQ:KROS$14.49 -0.60 (-3.98%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$14.70 +0.21 (+1.45%) As of 10/15/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Mineralys Therapeutics NASDAQ:MLYS$43.35 +0.55 (+1.29%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$43.66 +0.31 (+0.73%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Organon & Co. NYSE:OGN$9.55 -0.01 (-0.13%) Closing price 10/15/2025 03:59 PM EasternExtended Trading$9.61 +0.06 (+0.65%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Recursion Pharmaceuticals NASDAQ:RXRX$6.79 +0.90 (+15.28%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$6.84 +0.05 (+0.81%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
